Month: June 2022

A clinical trial shows positive results for the most common cutaneous lymphoma treatment with an immunosuppressive drug

Dr. Cristina Muniesa and Dr. Octavi Servitje, from the Dermatology Service of the Bellvitge University Hospital (HUB) and IDIBELL researchers, participated in this study that evaluates the use of topical pimecrolimus in mycosis fungoides and was published in the prestigious journal The Lancet Haematology.

A study describes a new way to generate insulin-producing cells

Researchers from the Karolinska Institute in Sweden, in collaboration with Meritxell Rovira from IDIBELL, the P-CMRC, and the UB show that a recently identified molecule stimulates the formation of new insulin-producing cells in zebrafish and in mammalian tissues.

Ernest Nadal presents at ASCO the benefits of treating patients with lung cancer and brain metastases with chemo-immunotherapy

A group from IDIBELL, Catalan Institute of Oncology, and the Spanish Lung Cancer Group (GECP) have shown that the combination of atezolizumab with carboplatin and pemetrexed is safe and effective as a first treatment option in a group of 40 patients.

Scroll to Top